Sanofi India’s board has approved the demerger of its consumer healthcare business into a separate entity, Sanofi Consumer Healthcare India Ltd (SCHIL). The move remains subject to shareholder and regulatory approvals.
Separate Focus for Pharma and Consumer Health
The restructuring aims to help both businesses pursue independent growth strategies. The pharmaceutical business will focus on expanding its portfolio of treatments and accelerating digital transformation. Meanwhile, SCHIL will adopt consumer-focused strategies and strengthen its digital and e-commerce capabilities.
As per ETHealthworld, Sanofi’s consumer healthcare business recorded an annual turnover of ₹730 crore in FY2022. Its key brands include Allegra, DePURA, Avil and Combiflam.
Shareholding Structure
Following the proposed demerger, Sanofi will retain a 60.4% stake in both entities. Existing Sanofi India shareholders will receive one SCHIL equity share for every Sanofi India equity share held.
The company expected SCHIL to become fully operational by the second half of 2024, subject to the required approvals. Sanofi’s vaccine and clinical study businesses in India will remain outside the restructuring.